SLC2A1 and schizophrenia: A diagnostic model based on the two most robust biomarkers, monocyte GLUT1 and T helper cell CD36, demonstrated good predictive performance when separating schizophrenia patients from healthy controls in three independent cohorts, as well as from patients with other relevant neuropsychiatric disorders, including autism spectrum condition, bipolar disorder and major depressive disorder.